Scottsdale, AZ, United States of America

Tong Wang

USPTO Granted Patents = 23 (Patent Applications = 9)

CIPO Patents = 1

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 2.3

ph-index = 3

Forward Citations = 21(Granted Patents)

Location History:

Phoenix, AZ (US) (2015 - 2017)
Scottsdale, AZ (US) (2015 - 2024)

Company Filing History:

13 out of 13

Translational Drug Development, LLC

patents

9 out of 119

The Translational Genomics Research Institute

patents

3 out of 26

Van Andel Research Institute

patents

4. 1 out of 1

Translation Drug Development, LLC

patent

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12076401 - Benzamide and active compound compositions and methods of use (2024-09-03),

2. 11780816 - Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase (2023-10-10),

3. 11555039 - Amide compounds as kinase inhibitors, compositions and methods of treatment (2023-01-17),

4. 11420947 - (S)-n-hydroxy-2-(2-(4-methoxyphenyl)butanamido)thiazole-5-carboxamide and pharmaceutically acceptable salts thereof (2022-08-23),

5. 11236052 - Aminobenzimidazole derivatives, treatments, and methods of inhibiting histone deacetylase (2022-02-01),

6. 10881733 - Benzamide and active compound compositions and methods of use (2021-01-05),

7. 10807966 - Heterocyclic compounds as kinase inhibitors (2020-10-20),

8. 10780080 - Benzamide and active compound compositions and methods of use (2020-09-22),

9. 10738007 - Amide compounds as kinase inhibitors, compositions and methods of treatment (2020-08-11),

10. 10633393 - Heterocyclic compounds as kinase inhibitors (2020-04-28),

11. 10590088 - 4-(benzimidazol-2-ylamino)benzamide derivatives and methods of synthesis thereof (2020-03-17),

12. 10584119 - Pyrazole compounds and methods of use thereof (2020-03-10),

13. 10544100 - Autophagy inhibitors (2020-01-28),

14. 10392402 - Heterocyclic compounds as kinase inhibitors (2019-08-27),

15. 10131654 - Pyrazole compounds and methods of use thereof (2018-11-20),

Title: The Innovative Contributions of Inventor Tong Wang

Introduction

Tong Wang is a notable inventor based in Scottsdale, AZ, with a remarkable portfolio of 23 patents to his name. His work primarily revolves around pharmaceutical compositions and methods that significantly contribute to cancer treatment. Wang's inventions showcase a dedication to enhancing therapeutic strategies through innovation.

Latest Patents

Among his recent patents, Wang has developed compositions that include a PD-1 axis binding antagonist and a CTLA4 antagonist, alongside a benzamide compound. This invention emphasizes methods for treating cancer by enhancing tumor immunogenicity, proving critical in advancing cancer therapies. Another notable patent involves novel aminobenzimidazole derivatives aimed at treating histone deacetylase (HDAC)-associated diseases. This invention focuses on inhibiting the activity of specific HDAC isoforms, thereby providing potential therapeutic avenues for various diseases.

Career Highlights

Throughout his career, Tong Wang has made significant contributions to the field of drug development. He has worked with esteemed organizations such as Translational Drug Development, LLC, and The Translational Genomics Research Institute. His experiences in these organizations have allowed him to influence the direction of innovative research and development within the pharmaceutical sector.

Collaborations

Wang has collaborated with various professionals, including notable coworkers like Stephen Gately and Paul Gonzales. These collaborations have played an essential role in furthering his research and driving innovative solutions in the pharmaceutical industry.

Conclusion

Tong Wang's innovative approach and dedication to advancing cancer treatment through his patented inventions underscore his valuable contributions to the medical field. With a solid background and collaborative efforts, Wang continues to inspire and influence the future of pharmaceutical research and development.

This text is generated by artificial intelligence and may not be accurate.